GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Aclaris Therapeutics Inc (FRA:8AT) » Definitions » Cyclically Adjusted FCF per Share

Aclaris Therapeutics (FRA:8AT) Cyclically Adjusted FCF per Share : €-1.90 (As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Aclaris Therapeutics Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Aclaris Therapeutics's adjusted free cash flow per share for the three months ended in Dec. 2024 was €-0.448. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-1.90 for the trailing ten years ended in Dec. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2025-04-17), Aclaris Therapeutics's current stock price is €0.967. Aclaris Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2024 was €-1.90. Aclaris Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Aclaris Therapeutics Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Aclaris Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aclaris Therapeutics Cyclically Adjusted FCF per Share Chart

Aclaris Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -1.90

Aclaris Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -1.70 -1.74 -1.60 -1.90

Competitive Comparison of Aclaris Therapeutics's Cyclically Adjusted FCF per Share

For the Diagnostics & Research subindustry, Aclaris Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aclaris Therapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Aclaris Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Aclaris Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


;
;

Aclaris Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Aclaris Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-0.448/133.1571*133.1571
=-0.448

Current CPI (Dec. 2024) = 133.1571.

Aclaris Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201503 -0.250 99.621 -0.334
201506 -0.139 100.684 -0.184
201509 -0.491 100.392 -0.651
201512 -0.194 99.792 -0.259
201603 -0.309 100.470 -0.410
201606 -0.422 101.688 -0.553
201609 -0.415 101.861 -0.543
201612 -0.329 101.863 -0.430
201703 -0.461 102.862 -0.597
201706 -0.344 103.349 -0.443
201709 -0.407 104.136 -0.520
201712 -0.514 104.011 -0.658
201803 -0.582 105.290 -0.736
201806 -0.614 106.317 -0.769
201809 -0.841 106.507 -1.051
201812 -0.620 105.998 -0.779
201903 -0.678 107.251 -0.842
201906 -0.464 108.070 -0.572
201909 -0.531 108.329 -0.653
201912 -0.449 108.420 -0.551
202003 -0.151 108.902 -0.185
202006 -0.228 108.767 -0.279
202009 -0.247 109.815 -0.300
202012 -0.167 109.897 -0.202
202103 -0.204 111.754 -0.243
202106 -0.188 114.631 -0.218
202109 -0.147 115.734 -0.169
202112 -0.247 117.630 -0.280
202203 -0.312 121.301 -0.342
202206 -0.285 125.017 -0.304
202209 -0.121 125.227 -0.129
202212 -0.272 125.222 -0.289
202303 -0.376 127.348 -0.393
202306 -0.273 128.729 -0.282
202309 -0.326 129.860 -0.334
202312 -0.093 129.419 -0.096
202403 -0.271 131.776 -0.274
202406 -0.160 132.554 -0.161
202409 0.278 133.029 0.278
202412 -0.448 133.157 -0.448

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Aclaris Therapeutics  (FRA:8AT) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Aclaris Therapeutics Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Aclaris Therapeutics's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Aclaris Therapeutics Business Description

Traded in Other Exchanges
Address
701 Lee Road, Suite 103, Wayne, PA, USA, 19087
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

Aclaris Therapeutics Headlines

No Headlines